Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2000 Sierra Point Parkway, Suite 501 BRISBANE CA 94080-1930 |
Tel: | N/A |
Website: | https://dayonebio.com |
IR: | See website |
Key People | ||
Garry A. Nicholson Chairman of the Board | Jeremy Bender President, Chief Executive Officer, Director | Samuel Blackman Co-Founder, Head of Research and Development |
Charles N. York Chief Financial Officer, Chief Operating Officer, Secretary | Lauren Merendino Chief Commercial Officer | Raphael F. Rousseau Chief Medical Officer |
Business Overview |
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing targeted therapies for patients of all ages with life threatening diseases. The Company seeks to identify, acquire and develop product candidates that target high-value oncogenic drivers in cancers with unmet needs, with an initial focus on pediatric patients. Its lead product candidate, tovorafenib (DAY101), is an oral, brain-penetrant, highly selective type II pan-rapidly accelerated fibrosarcoma (pan-RAF), kinase inhibitor. Its second product candidate, pimasertib, is an oral, highly selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a well-characterized key signaling node in the MAPK pathway. It has initiated an open-label, multicenter, Phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib monotherapy or combination therapy, which consists of two substudies, such as Substudy 1 and Substudy 2. |
Financial Overview |
For the fiscal year ended 31 December 2023, Day One Biopharmaceuticals Inc revenues was not reported. Net loss increased 33% to $188.9M. Higher net loss reflects Research and development increase of 51% to $116.1M (expense), General and administrative - Balancing increase of 19% to $50.6M (expense), Stock-based Compensation in SGA increase of 33% to $25M (expense). |
Employees: | 155 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,013M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$206.03M as of Dec 31, 2023 |
Net annual income (TTM): | -$188.92M as of Dec 31, 2023 |
Free cash flow (TTM): | -$147.08M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 87,384,856 as of Feb 21, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |